



Compliance Alert

August 24, 2009

Express Scripts – Urgent –Emerging Therapeutic Issue

Barr Laboratories, Inc. announced a voluntary recall of a single lot (#311756) dextroamphetamine/amphetamine (generic for Adderall) 20mg tablets because some product may contain more drug than listed on the label. According to the manufacturer, taking too much of the drug can result in cardiovascular, neurological, psychiatric and gastrointestinal reactions including headache, dizziness, blurred vision, insomnia, agitation and anxiety. The affected lot number was distributed between June 11 and June 16.

If you have additional questions, you can call Barr's customer service at 888.742.5578, Monday through Friday, 8:00 a.m. – 8:00 p.m. EDT. Additional information can be found on FDA's MedWatch website at: www.fda.gov/medwatch . You can also call FDA at 1.888.INFO.FDA (automated) or 301.796.3400.

Express Scripts' response:

- In an effort to inform members of this recall, we have identified members who have received a prescription for dextroamphetamine/amphetamine 20mg tablets manufactured by Barr filled after June 11, 2009, the date the affected lot was first distributed. A communication summarizing the information provided by the manufacturer will be sent to these members.
- The above communication will be distributed for those clients enrolled in the member portion of the Emerging Therapeutic Issues Patient Safety Program.
- Express Scripts will also distribute letters to all patients who have filled a prescription for a recalled product using Express Scripts Home Delivery services.

If you have any questions regarding this information, please contact your Group Benefit Services Account Manager at 1.800.638.6085.

This communication is not intended to be legal advice and should not be construed as legal advice. If you have any legal questions or concerns about your plan, GBS recommends seeking counsel from an ERISA attorney.

Keeping you informed. Just one more reason to choose GBS.